Just weeks after enduring a storm of controversy triggered by his initial refusal to provide a potent but experimental antiviral to a dying child under a compassionate use program, Chimerix CEO Ken ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback